Evaxion Biotech A/S Q2 2023 Earnings Call Transcript

Quartr
Provided by Quartr
August 22, 2023

There are 6 speakers on the call.

Operator

Good day, and thank you for standing by. Welcome to the Evaxion Biotech Q2 Results Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded.

Operator

I would now like to hand the conference over to your speaker today, Per Nollen, please go ahead.

Speaker 1

Thank you, operator. Good morning and good afternoon, everyone. I'm Per Noren, Chief Executive Officer at Avaktion. And with me today is Jesper Nygard Nissen, Chief Operating Officer and Interim And Interim Chief Financial Officer at Avaktion since August 1. First, before we start a note on forward looking statements, Let me remind you that the following discussion contains certain statements that are considered forward looking statements as defined in the Private Securities Litigation Reform Act of 1995.

Speaker 1

Because forward looking statements involve risks and uncertainties, they are not guarantees of future performance, And actual results may differ materially from those expressed or implied by these forward looking statements due to a variety of factors, including those risk factors discussed In the company's Annual Report Form 20 F and the company's current and future reports submitted to the Securities and Exchange Commission, SEC. With that said, I'm pleased to welcome you to today's conference call. During the call, I will provide you with a brief overview Of the excellent progress we made across our pipeline and on our core AI technologies over the past 6 months. I will then turn the call over to Jesper, who will review our financial report for the Q2 of 2023, and then we will open up the line for questions. We have a presentation which you can follow, and this is Slide 1.

Speaker 1

And we will start by taking a quick look at today's agenda, which is on Slide 2. So Slide 2. I will start with our recent communication on our staphylococcus aureus vaccine, EVXB1, Well, we were pleased to present preclinical proof of concept data showing that the vaccine candidate can clear staphylococcus infections. We will also show the early stage clinical data reported on AACR 2023 and ASCO 23, Indicating that patients treated with our vaccines, EVX-one or EVX-two, in combination with the checkpoint inhibitor, update on our next generation personalized cancer vaccine candidate, EVX-three, which is approaching the clinic, As well as our novel AI technology, Observe, has been used to identify a new source of antigens for personalized cancer vaccines. And that's planned for clinical validation through the EVX-three program.

Speaker 1

And of course, the financial update with the 2nd quarter financial results as presented So let's start with EVX V1 on Slide 3. So move to Slide 3. In late July, we presented novel data on our vaccine candidate for prevention of Stetylococcus Aureus disease, EDEX B1, at the Gordon Research Conference in New Hampshire, USA. The vaccine candidate has been generated using our AI technology And apart from the protective effect demonstrated in the sepsis disease model, which we have shown previously and that you can see for reference on the left hand side, We have now assessed the ability of EDX B2 to clear bacteria from internal organs. And if you take a brief look at the graph on the right hand side, The results are quite clear.

Speaker 1

No bacteria could be detected in any organs 4 weeks after bacterial challenge. The program is currently in late preclinical development, and we are in discussions with a potential partner on its future development in accordance with our strategy. So now let's switch to oncology and our clinical programs for personalized cancer vaccines. That's Slide 4. So if you have the right slide in front of you, you should be able to read EDEX-one on the top, And it should show the readout of our clinical Phase III clinical trial in metastatic melanoma.

Speaker 1

EVX-one is a personalized peptide based Cancer vaccine, where patient specific tumor mutations so called neoantigens are identified using our AI technology Pioneer. These neoantigens are ideal targets for cancer vaccine in that they derive from tumor mutations and therefore only exists in tumor cells, which means that the treatment can become very specific for the tumor with less risk of negative effects on healthy tissue. In the first in human trial, 6 biweekly doses of EDX-one were given in combination with PD-one therapy. The treatment was well tolerated. And of the 12 patients that completed the trial, 8 showed an objective response To the treatment, if you look on the graph on the right hand side, you should see a horizontal black line indicating the tumor size at the start of treatment.

Speaker 1

You can see 12 bars, which represents the best objective responses for each patient in the trial. If the bar goes up, tumors increase in size. And if the bar goes down, this means that tumors decrease in size. And to our excitement, Most bars do actually go down. And for 8 of the patients, the outcome fulfills the criteria of a treatment response.

Speaker 1

We're obviously really enthusiastic about these results. It's better than what you would expect from PD-one alone, And it speaks to the strength of our AI technology in selecting the right new antigens for personalized cancer vaccine. This was EVX-one, but we have also reported data from our DNA based cancer vaccine, EVX-two. That's on the next slide, Slide 5. It should say EDX-two at the top.

Speaker 1

This is a clinical trial of EVX-two in combination with nivolumab, a PD-one blocker, as adjuvant therapy to prevent cancer relapse After complete surgical resection on malignant melanoma over 12 months. It's a DNA based therapy. The image shows a DNA plasmid carrying the genes for patient specific neoantigens. So the vaccine is administered as DNA And then translated to neoantigens in the patients and the results look very promising. All ten patients that have completed the vaccination with EDX-two were relapse free at the end of the trial.

Speaker 1

The vaccine was well tolerated in all patients And induced a new antigen specific T cell immune response in all patients, which can be seen as a proof of mechanism for our DNA vaccine technology. But we do not plan to develop this vaccine candidate further for the time being. And why, you may ask? Well, it's because we have already developed a next generation vaccine based on EVX-two and the new candidate is called EVX-three and which we intend to prioritize. Let's move to Slide 6.

Speaker 1

So, EDX-three. EDX-three is the first ever personalized herb cancer vaccine. It builds on IDEXXO2, meaning that it's a DNA based personalized cancer vaccine, but it has 2 major upgrades. One upgrade is the addition of a genetic immune adjuvant, which aims to boost the immune system immune response To the vaccine, the other upgrade is the addition of a novel vaccine target, so called herbs, which I will come back to in a minute. Let's start with the genetic immune adjuvant.

Speaker 1

This is a chemoattractant molecule, which is incorporated into the DNA plasmid As shown for EVX03 to the right of the picture. EVX02 is a plasmid on the left hand side incorporating DNA coding for neoantigens, Whereas EBX-three on the right hand side, in addition, incorporates the DNA sequence for the genetic immune adjuvant, which is shown in green. The DNA plasmid is administered to the patient and the adjuvant, a chemoattractant molecule called CCL19 Is produced inside the cells of the patient at the injection site. And the consequence of this is that the genetic adjuvant attracts immune cells to the vaccination Which is thought to make the vaccine much more effective. Preclinical data supporting these claims were presented in detail at our R and D Day in May, And you're welcome to visit those presentations at our homepage.

Speaker 1

The second upgrade of EBXO3 is on the antigen side. Personalized cancer vaccines are usually dependent on neoantigens, which are created by mutations in the tumor. This is how the immune system can identify and attack tumors. But it's not the only way for the immune system to identify tumor. Using artificial intelligence and specifically our novel AI technology, Observe, We have identified a novel source of tumor selective antigens that can be used for personalized cancer vaccines, So called IRFs, which stands for endogenous retroviruses and which are also included in EDEXA-three as shown to the right.

Speaker 1

Let's switch to Slide 7 and our novel AI platform, Observe. So Slide 7. Observe, it's our AI technology for identification of herbs and herbs constitute novel source of cancer vaccine antigens That may allow effective treatment also patients who are unresponsive to today's cancer immunotherapies. But what are herbs? Well, Herbs are viral DNA leftovers from historical infections throughout human history.

Speaker 1

And we all have it. In fact, about 8% of our DNA has viral origin. But no need to worry, this DNA is resting and do no harm to us, At least not under normal conditions where IRFs are under tight control by our genetic machinery. But in cancer cells, these control mechanisms Often breakdown leading to selective expression of HERFs on human cancer cells. And these HERFs are, of course, ideal targets for the immune system.

Speaker 1

The cancer cell basically waits with a red flag saying, I don't belong here. I'm infected by a virus and potentially leading to an immune attack. And that seems to happen quite regularly. We have recently shown that patients that produce herbs in the tumors may survive longer. If you Take a look on the left hand side in this slide.

Speaker 1

You can see 2 survival curves in patients with low tumor mutation burden sorry, Low tumor mutational burden or TMB, which means that there are few tumor mutations. The red line shows The survival in patients with few herbs, whereas the blue line shows the longer survival in patients with a lot of herbs, Presumably because such tumors with a lot of birds are more likely to be attacked by the immune system and hence the better survival. And in preclinical models, we have shown that this can be used to make a personalized cancer vaccine that effectively combats tumors. So we believe that EDEXO3 may be more effective than current vaccines that are based only on neoantigens. And notably that it can be broadened we can broaden the target population quite significantly.

Speaker 1

So Why is that? Why do we think we can broaden the target population? It's because today's immunotherapies are more or less restricted to patients with hot tumors, Which are tumors where there are many tumor mutations called the tumors with high tumor mutation burden or high TMD. But herbs seem to be equally highly expressed in tumors with few mutations or also called cold tumors. And these actually make up the majority of all patients' tumors.

Speaker 1

So potentially a much larger target population. We should remember that EDXO3 will contain both neoantigens and IRFs and also our novel genetic adjuvant technology. And that's why we refer to EDEXO-three as a next generation personalized cancer vaccines with potential for superior effects. So we plan to submit an application for start of Phase 1 clinical trial for EVX-three in Q4 this year and expect to be 1st in the world with a personal So in addition to the operational progress, we have recently Signed an agreement with the Global Growth Holding Limited, including financial commitments totaling up to US20 $1,000,000 Available in tranches over the next 3 years, subject to SEC approval. The financing is intended to cover the company's working capital needs, including the advancement of EDXO3 to Phase I readiness, while the actual initiation of clinical activities for EDXO3 or subject to additional funding.

Speaker 1

This was the updates from the operations. And now I would like to turn the call over to Jesper.

Speaker 2

Thank you, Peer. I will focus my comments on our financial results For Q2 2023 compared to Q2 2022, all of the numbers that I will review in this discussion will be approximate For additional information regarding our Q2 results and prior period comparisons, Please refer to the business update and Q2 2023 financial results press release and our Form 6 ks both filed last week. Starting with our expenses, research and development expenses for Q2 2023 Amounting to US2.9 million dollars and general and administrative expenses to US2.7 million dollars for the period. Research and development decreased by US1.2 million dollars or about 29% compared to the same period last year. The decrease was primarily driven by a decrease in external development cost of $700,000 related to clinical trial activities.

Speaker 2

Further, a decrease was seen in employee related costs of $500,000 due to reduced headcount in personnel. General and administrative expenses increased by $600,000 or 28% Compared to the same period last year, the increase was primarily due to an increase of $300,000 in external costs Related to professional fees and overhead and an increase in employee related cost of 200,000. These increases are due to the timing of funding projects and business initiatives compared to 2022 and the expansion of the organization throughout Free amounted to a loss of US5.7 million dollars compared to a loss of US4.8 million dollars for the same period last year. As of June 30, 2023, we have US7 $100,000 in cash and cash equivalents. We expect our cash balance to be sufficient to fund operations into December 2023.

Speaker 2

Now I would like to turn the call back to you, Bjorn, for closing remarks before Q and

Speaker 3

A. Thank

Speaker 1

you, Jesper. And now a brief look into the future. So looking into the rest of 2023, we expect to deliver on 2 important and near term milestones. We plan to report interim results From the ongoing EVX-one Phase II trial in patients with metastatic melanoma in Q4 this year. And also in Q4, to submit a clinical trial application to start a Phase 1 study for EBXO3.

Speaker 1

But as mentioned before, this is subject to additional funding in the range of $5,000,000 to $10,000,000 secured before initiation. So in conclusion, I'm very happy about the progress and believe we have potential to develop vaccines that may truly improve the treatment of cancer as well as the prevention of infectious disease around the world. On behalf of everyone at Avaxion, I invite you to continue to stay in touch with the company and follow progress in 2023 beyond. So operator, over to you for Q and A.

Operator

Thank you.

Speaker 4

Hey, guys. This is Thomas from Lake Street. A couple of quick questions. Per, you mentioned in your prepared remarks that you were discussing the staph aureus program with a partner. Has the deal been struck there?

Speaker 4

Or is this part of a partnership discussion for a deal yet to be announced?

Speaker 1

So Say that again. What was the question if we already have announced the partner or?

Speaker 4

Well, you mentioned that you were discussing with a partner of the future for the Staph Aureus I was curious if there was a partnership that had already been struck or is this with a potential partner?

Speaker 1

Yes. Thank you for that question, Thomas. Yes. So sorry, if that was confusing. Yes, I would refer to our strategy for these infectious disease programs, which is to find partnerships quite early.

Speaker 1

So we are in partnership discussion on some of our assets and including this product, and we have not yet announced the partnership. So that will be done in due time when a partnership is in place. But we do not have we have not signed a partnership yet.

Speaker 4

Got it. And then for the EVX-one readout in the Q4, I believe last time last quarter, you thought that you might have up to 20 patients In that readout, do you have any updates for us on how many patients you expect to have and what format that release will come in press release versus the scientific meeting?

Speaker 1

Yes. We intend to present the interim data at the end of this year at One of the important, well, cancer conferences and SITC could be one such conference, but it's yet to be finally determined. And we expect to present data from the first, say, handful of patients. But as you say, we have Recruited patients, but we have also reduced the size of the trial. So currently, it looks to be Slightly less than 20 patients, the exact number of patients to be determined.

Speaker 1

But as you say, we will report to the first handful of patients Towards end of the year at the conference.

Speaker 4

Excellent. And then just one final one. The cash runway into the Q4, does that depend on Additional use of the ATM or the Lincoln Park facility? Or can you get into December using the 7.1% that you had at the end of June?

Speaker 1

Yes, that's correct. So that the runway is currently communicated without assumption that we get additional funding.

Speaker 4

Excellent. I appreciate you taking the questions. Thank you.

Speaker 1

Thanks so much.

Operator

Thank you. We will now take the next question from the line of Ahu Demir, please state your company name and ask your question.

Speaker 5

Good morning and good afternoon. I am Ahu Demir Calling from Ladenburg Thalmann. Two questions from us. One follow-up to Thomas's question about EVX-one Phase 2 studies, how many of the patients are in the priming stage? Are all patients are In the priming stage versus boosting stage?

Speaker 5

And do you plan to follow-up these patients and continue with the boosting stage as well?

Speaker 1

Yes. So to the trial and as you referred to thank you, Ahu, for the question. We have this is trial where we combine with PD-one and which is given to the patients the 1st 3 months And then they continue and then we give the vaccine in combination. So we have Initiated vaccine treatments with EVX-one in a bit more than a dozen patients, And we are expecting to administer the vaccine to the last few patients quite soon. So It's all more or less closing in on the number of patients we have in the trial.

Speaker 1

So, sure did that answer your question?

Speaker 5

So all the patients will actually have the boosting basically. So it will be, as I understand, between week 12 to 24, you have the timing section. So these are the patients you have a much longer follow-up.

Speaker 1

Yes. Sorry. Now I understand. So yes, We do not know that yet. So it's quite a lot of patients has been entering the trial during the spring.

Speaker 1

So we're not yet there where we will know if they will go into the next phase of boosting. But that is the plan for patients if they Stay on the trial and if they're not progressing that they will be offered boosting.

Speaker 5

I see. So all the patients will see End of this year would be at the timing stage basically?

Speaker 1

Yes. That will be the date that we will present at the end of this year, yes.

Speaker 5

Okay. Helpful to know. And my second question is on the earth. This is something relatively new compared to new antigen approach. So I am curious, How do you select your IRF?

Speaker 5

How specific are they among patients or within an indication? Just curious If you could elaborate on the IRVE side?

Speaker 1

Yes. I can give some more background. So there's a lot of the IRVE DNA in All humans, and as I said before, these are more or less randomly expressed in some cancers when the machine control machinery breaks down. That seem to be around, say, 10000 or 20000 different euros that can be expressed. So finding they are very different from patient to patient.

Speaker 1

And that said, there are sometimes in Some patients that could be overlapping herbs, but we are in this trial looking for Producing a fully personalized vaccine towards herbs. And that's really where we are unique. So and these herbs, They are selected based on likelihood to induce a strong immune response. Given that there are relatively long Foreign peptides, there can be actually quite large number of epitopes on each herb. So we can find very, So say high quality antigens whenever we find strong expression of these herbs in patients.

Speaker 1

And it's based more or less in the same way as when you select the new antigens that you look for How well they match the immune system of that patient? So you need to predict the shape of the patient's immune receptors and also the shape Of the epitopes on the herb and then how likely they are to adhere to one another, That is one of the key factors we look at, but there are many more aspects to it.

Speaker 5

Got it. Thank you very much for taking my questions.

Speaker 1

Thanks so much, Erud.

Operator

Thank you. It comes from the line of Swayampakula Ramakanth. Please state your company name and ask your question.

Speaker 3

Thank you. This is RK from H. C. Wainwright. Good afternoon, Per.

Speaker 3

So a quick question on So on the Phase 1 portion of that study, You have presented some interim data on the 9 patients. Is there going to be additional data in the next The update that you're going to be presenting at the end of this year or is it mostly going to be Initial data from the Phase II portion of the study?

Speaker 1

Yes. Thank you, RK, for that question. So at ASCO this year, we Presented the full data set. So as you mentioned, we previously have shown interim data from 9 patients. But at ASCO in June, we presented and the slide that's in the presentation today is section 12 patients, which is a full patient set, Well, we do have 8 responders.

Speaker 1

So there we have already presented the data. We will likely publish this more scientific details later on, but we don't intend to present additional clinical outcome data on these Program, so that's already final. At the end of this year, we will focus on the interim data of the Phase II trial, which It's a slightly different design and it's then sites in Australia and in Europe. So it's a multicenter trial.

Speaker 3

Very good. And then on the IRFs, I'm just trying to understand

Speaker 2

a little bit more on

Speaker 3

the IRFs. Are the IRFs Expressed uniquely based on the patient or are they Uniquely based on the indication?

Speaker 1

Yes. That question, I would say, is uniquely based on Patient, we think there could be some overlaps sometimes depending on the cancer. And Maybe if you'll reason around how they're expressed, if the sort of if there is a signal to express a certain part of the genes In a patient, then if that signal is common between patients, there may be an overlap between those herbs. But usually The expression of those is completely independent. So to answer your question a bit more simply, we think it's highly patient But with the potential to find some overlap, we didn't are not looking for overlap in the first trial.

Speaker 1

So there is Fully personalized, but it's possible that you can find a subpopulation where there is some overlap and you can produce a common drug for several patients.

Speaker 3

So one last question on the IRVE again. Do you need is there a certain threshold In terms of expression of the IRF, for you to make a personalized vaccine against it or Yes.

Speaker 1

And that's a very good question, I think, because this is really the key challenge with neoantigens that you need a lot mutations in order to find enough high quality neoantigens to make a vaccine. And that's really why personalized cancer vaccines today are restricted To say melanoma, a few more indications, lung cancer and so on. And in other indications where there are a few mutations, maybe it's just a few percent of the patients where you can actually make a personalized NIVE antigen vaccine. With IRFs, we find a slightly different profile. It's So not the same indications where they're highly expressed.

Speaker 1

It's often expressed in patients with cold tumors. So It really allows for treating making a cancer vaccine for patients with a completely cold tumor without any neoantigens. And but in the EDEXO-three, we actually plan to do both. We will sequence the tumor. And if they have good neoantigens, They will this will be included in the vaccine and then it will be complemented by strong herbs at the same time.

Speaker 1

So we try to pick the best from both worlds And hopefully, we can also expand the Page target group quite significantly.

Speaker 3

Thank you. Thanks for taking all my questions.

Speaker 1

Thank you so much, RK.

Operator

Thank you. There are no further questions at this time. I would like to hand back over to Per for final remarks.

Speaker 1

Okay. Bye.

Operator

That does conclude our conference for today. Thank you for participating. You may now disconnect.

Powered by Quartr

Key Takeaways

  • Preclinical data for the staphylococcus aureus vaccine candidate EVX-B1 showed complete bacterial clearance from organs four weeks post-challenge, and the program is in late preclinical development with partnership discussions underway.
  • In the Phase I trial of the personalized peptide vaccine EVX-one plus PD-1 therapy in metastatic melanoma, 8 of 12 patients achieved an objective response, outperforming expectations for PD-1 alone.
  • The DNA vaccine EVX-two yielded 100% relapse-free survival and induced antigen-specific T-cell responses in 10 resected melanoma patients, but will not be further advanced in favor of the next-generation candidate.
  • The next-generation personalized cancer vaccine EVX-three combines a DNA-encoded chemoattractant adjuvant (CCL19) with tumor-selective endogenous retrovirus antigens identified by the Observe AI platform, with a Phase I clinical trial application planned for Q4 2023 (pending additional funding).
  • The proprietary AI platform Observe uncovers endogenous retrovirus-derived antigens (HERVs) in tumors—particularly “cold” tumors with low mutation burden—potentially broadening vaccine applicability beyond current neoantigen-only approaches.
AI Generated. May Contain Errors.
Earnings Conference Call
Evaxion Biotech A/S Q2 2023
00:00 / 00:00